Godavari Biorefineries Limited (GBL) has announced the incorporation of Sathgen Therapeutics LLC, a wholly-owned step-down subsidiary based in Princeton, New Jersey, USA. This strategic expansion aims to strengthen GBL's clinical-stage biotechnology presence in the United States, with a primary focus on global out-licensing of intellectual property and accelerating drug development programs. Sathgen Therapeutics originated from an initiative by Dr. Sendurai Mani, supported by Mr. Samir Somaiya, Chairman and Managing Director of GBL. The subsidiary's research efforts have led to promising preclinical efficacy in triple-negative breast cancer (TNBC) and novel compounds that inhibit cancer and cancer stem cells in vitro. Patents have been secured in the US, Europe, and China. Dr. Padmaja Ganpathy will serve as the CEO of Sathgen Therapeutics LLC, and Dr. Sendurai Mani will be the Chief Scientific Officer. The company also announced the formation of a Scientific Advisory Board (SAB) comprising Dr. Razelle Kurzrock and Dr. Massimo Cristofanilli, who will guide the clinical development and translational research strategy. Samir Somaiya stated that the establishment of Sathgen Therapeutics LLC represents a new chapter in translating science into meaningful solutions, addressing the challenge of TNBC. Dr. Ganpathy emphasized the U.S. presence as a platform for partnerships to advance technologies, while Dr. Mani highlighted the focus on targeting cancer stem cells to impact conditions like TNBC. Dr. Sangeeta Srivastava, Executive Director of GBL, noted that the U.S. subsidiary will accelerate clinical programs and foster research collaborations.